InnoSerからのニュースと最新情報

Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases

Feb 25, 2025 | Neurology, Newsletter

With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...

マウスデータを用いたPK/PD関係の確立による前臨床研究の推進方法

2025年2月24日|ブログ、神経学

The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...

InnoSer International Announces Leadership Transition: Kris Motmans Appointed as New CEO

Feb 18, 2025 | News

Diepenbeek, Belgium, Feb 17, 2025 — InnoSer International, a leading preclinical Contract Research Organization (CRO) specializing in innovative solutions for drug development, proudly announces the appointment of Kris Motmans as the new Chief Executive Officer. This...

MDX Mouse Model Validation Data

Dec 5, 2024 | Neurology, Newsletter

This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...